bioAffinity Technologies, Inc. held its 2023 Annual Meeting of Stockholders on June 6, 2023, both in person at the Company’s principal office in San Antonio, TX, and virtually via a live webcast on June 6, 2023. Shareholders were entitled to cast one vote per share of common stock held as of the close of business on the record date of April 14, 2023. Proxy ballots were cast by stockholders representing 6,433,619 shares, 75.43% of shares entitled to vote.
At the Annual Meeting, the Company’s stockholders approved the following proposals:
- To elect seven directors to serve on the Board until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified;
- To consider and approve an amendment to the bioAffinity Technologies, Inc. 2014 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance with respect to awards granted under the Incentive Plan from 1,142,857 shares to 2,000,000 shares;
- To consider and approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock authorized for issuance from 14,285,715 shares to 25,000,000 shares; and
- To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
A recording of the meeting is available here.
